Zoetis Inc.
ZTSNYSEDrug Manufacturers - Specialty & Generic • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for ZTS
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for ZTS
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 6 Aug 2026
Q2 Revenue Flat, EPS Beats
Zoetis reported second-quarter 2026 revenue of $2.5 billion, flat year-over-year but down 1% on an organic operational basis, with net income of $691 million or $1.65 per diluted share. Reported diluted EPS of $1.87 per share exceeded the same-quarter consensus estimate of $1.85 per share.
U.S. Companion Animal Sales Decline
U.S. segment revenue totaled $1.3 billion, decreasing 7% on both a reported and organic operational basis.
International Segment Growth
International segment revenue reached $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis.
Full-Year 2026 Guidance Revised
The company revised full-year 2026 revenue guidance to $9.120 billion to $9.320 billion, implying organic operational revenue growth of (3)% to (1)%. Guidance for adjusted diluted EPS was revised to $6.15 to $6.25.
Cost of Sales Margin Stable
Cost of sales as a percentage of revenue was approximately 29.2% for the quarter, representing a 0.2 percentage point increase compared to the prior year period.
Simparica Trio EUA and Leadership
FDA for its Simparica Trio chewable to treat New World screwworm infestations in dogs and puppies, while appointing Jay Saccaro as Chief Financial Officer and Chief Operating Officer.
Price Chart
NYSE:ZTS via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
ZTSZoetis Inc. | $77.34 | $32.0B | — | 12.5x | +1.4% | 71.5% | 7.4% |
Company Profile
About the Company
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Next Earnings Date
Nov 3, 2026
Loading latest news...